Adolor Corporation to Present at the Cowen and Company 29th Annual Health Care Conference

Adolor Corporation (Nasdaq:ADLR) today announced that Michael R. Dougherty, President and Chief Executive Officer, will present at the Cowen and Company 29th Annual Health Care Conference on Monday, March 16, 2009 at 3:55 P.M. Eastern Time. The conference is being held at the Boston Marriott Copley Place, Boston, Massachusetts.

Adolor’s presentation will be webcast live for investors through www.adolor.com and available for a period of one week following the conference.

About Adolor Corporation

Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.

Adolor’s first approved product in the United States is ENTEREG®, which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is available for short-term use in hospitals registered under the ENTEREG Access Support and Education (E.A.S.E.TM) Program. In collaboration with GlaxoSmithKline, the Company launched ENTEREG in mid-2008.

The Company’s research and development pipeline includes: two novel delta opioid receptor agonists, currently in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; a mu opioid receptor antagonist entering development for chronic opioid bowel dysfunction (OBD); and several opioid and non-opioid discovery programs.

For more information, visit www.adolor.com.

This press release is available on the website http://www.adolor.com.